Next Article in Journal
Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy
Next Article in Special Issue
Invertebrate Models Untangle the Mechanism of Neurodegeneration in Parkinson’s Disease
Previous Article in Journal
PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer
Previous Article in Special Issue
Identification of Cathepsin D as a Plasma Biomarker for Alzheimer’s Disease
 
 
Review

Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway

1
Department of Clinical Research and Innovation (DRCI), Hôpital Foch, 92150 Suresnes, France
2
Centre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules Verne (UPJV), 80054 Amiens, France
3
Laboratoire de Mathématiques et Applications (LMA), UMR CNRS 7348, Université de Poitiers, 86021 Poitiers, France
4
Centre de Recherche Clinique, Grand Hôpital de l’Est Francilien (GHEF), 6-8 rue Saint-Fiacre, 77100 Meaux, France
*
Author to whom correspondence should be addressed.
Academic Editors: Pyotr A. Slominsky and Maria Shadrina
Cells 2021, 10(2), 230; https://doi.org/10.3390/cells10020230
Received: 25 November 2020 / Revised: 4 January 2021 / Accepted: 8 January 2021 / Published: 25 January 2021
(This article belongs to the Collection Advances in Neurodegenerative Disease)
Parkinson’s disease (PD) is one of the major neurodegenerative diseases (ND) which presents a progressive neurodegeneration characterized by loss of dopamine in the substantia nigra pars compacta. It is well known that oxidative stress, inflammation and glutamatergic pathway play key roles in the development of PD. However, therapies remain uncertain and research for new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on PD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3beta, the main inhibitor of the WNT/β-catenin pathway. The stimulation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in PD. View Full-Text
Keywords: WNT/beta-catenin pathway; lithium; Parkinson; inflammation; oxidative stress; glutamatergic pathway WNT/beta-catenin pathway; lithium; Parkinson; inflammation; oxidative stress; glutamatergic pathway
Show Figures

Figure 1

MDPI and ACS Style

Vallée, A.; Vallée, J.-N.; Lecarpentier, Y. Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. Cells 2021, 10, 230. https://doi.org/10.3390/cells10020230

AMA Style

Vallée A, Vallée J-N, Lecarpentier Y. Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. Cells. 2021; 10(2):230. https://doi.org/10.3390/cells10020230

Chicago/Turabian Style

Vallée, Alexandre, Jean-Noël Vallée, and Yves Lecarpentier. 2021. "Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway" Cells 10, no. 2: 230. https://doi.org/10.3390/cells10020230

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop